Christine Chable-Bessia

Nov 25, 2024 | tandfonline.com | Daouda Abba Moussa |Mario Vázquez |Christine Chable-Bessia |Vincent Roux-Portalez

AbstractUnlocking the potential of broadly reactive coronavirus monoclonal antibodies (mAbs) and their derivatives offers a transformative therapeutic avenue against severe COVID-19, especially crucial for safeguarding high-risk populations. Novel mAb-based immunotherapies may help address the reduced efficacy of current vaccines and neutralizing mAbs caused by the emergence of variants of concern (VOCs).